Anish Bhatnagar - 27 Mar 2025 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Signature
/s/ Anish Bhatnagar
Issuer symbol
SLNO
Transactions as of
27 Mar 2025
Transactions value $
-$40,898,099
Form type
4
Filing time
31 Mar 2025, 19:00:18 UTC
Previous filing
23 Jan 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLNO Common Stock Sale -$936K -14.2K -1.89% $65.97 738K 27 Mar 2025 Direct F1, F2, F3
transaction SLNO Common Stock Sale -$1.54M -23.1K -3.13% $66.79 715K 27 Mar 2025 Direct F1, F3, F4
transaction SLNO Common Stock Sale -$2.84M -42K -5.87% $67.70 673K 27 Mar 2025 Direct F1, F3, F5
transaction SLNO Common Stock Sale -$3.8M -55.2K -8.21% $68.79 618K 27 Mar 2025 Direct F1, F3, F6
transaction SLNO Common Stock Sale -$2.23M -32K -5.18% $69.84 586K 27 Mar 2025 Direct F1, F3, F7
transaction SLNO Common Stock Sale -$233K -3.29K -0.56% $70.73 583K 27 Mar 2025 Direct F1, F3, F8
transaction SLNO Common Stock Sale -$343K -4.78K -0.82% $71.74 578K 27 Mar 2025 Direct F1, F3, F9
transaction SLNO Common Stock Sale -$53.2K -732 -0.13% $72.64 577K 27 Mar 2025 Direct F1, F3, F10
transaction SLNO Common Stock Options Exercise $639K +26.6K +4.61% $24.00 604K 27 Mar 2025 Direct F3
transaction SLNO Common Stock Options Exercise $417K +16.7K +2.76% $25.05 620K 27 Mar 2025 Direct F3
transaction SLNO Common Stock Options Exercise $3.53M +105K +16.93% $33.60 725K 27 Mar 2025 Direct F3
transaction SLNO Common Stock Options Exercise $164K +32.2K +4.44% $5.10 758K 27 Mar 2025 Direct F3
transaction SLNO Common Stock Options Exercise $150K +62.3K +8.22% $2.41 820K 27 Mar 2025 Direct F3
transaction SLNO Common Stock Options Exercise $1.48M +281K +34.28% $5.25 1.1M 27 Mar 2025 Direct F3
transaction SLNO Common Stock Sale -$7.01M -106K -9.67% $65.81 994K 27 Mar 2025 Direct F3, F11
transaction SLNO Common Stock Sale -$13.9M -210K -21.09% $66.33 785K 27 Mar 2025 Direct F3, F12
transaction SLNO Common Stock Sale -$567K -8.42K -1.07% $67.37 776K 27 Mar 2025 Direct F3, F13
transaction SLNO Common Stock Sale -$13.8M -199K -25.66% $69.30 577K 27 Mar 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLNO Employee stock option (right to buy) Options Exercise $0 -26.6K -99.77% $0.00 60 27 Mar 2025 Common Stock 26.6K $24.00 Direct F14
transaction SLNO Employee stock option (right to buy) Options Exercise $0 -16.7K -100% $0.00 0 27 Mar 2025 Common Stock 16.7K $25.05 Direct F14
transaction SLNO Employee stock option (right to buy) Options Exercise $0 -105K -75% $0.00 35K 27 Mar 2025 Common Stock 105K $33.60 Direct F15
transaction SLNO Employee stock option (right to buy) Options Exercise $0 -32.2K -79.16% $0.00 8.47K 27 Mar 2025 Common Stock 32.2K $5.10 Direct F16
transaction SLNO Employee stock option (right to buy) Options Exercise $0 -62.3K -54.17% $0.00 52.7K 27 Mar 2025 Common Stock 62.3K $2.41 Direct F17
transaction SLNO Employee stock option (right to buy) Options Exercise $0 -281K -58.33% $0.00 201K 27 Mar 2025 Common Stock 281K $5.25 Direct F18
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2 This transaction was executed in multiple trades at prices ranging from $65.15 to $66.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F4 This transaction was executed in multiple trades at prices ranging from $66.24 to $67.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $67.24 to $68.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 This transaction was executed in multiple trades at prices ranging from $68.24 to $69.225. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7 This transaction was executed in multiple trades at prices ranging from $69.24 to $70.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F8 This transaction was executed in multiple trades at prices ranging from $70.24 to $71.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F9 This transaction was executed in multiple trades at prices ranging from $71.26 to $72.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F10 This transaction was executed in multiple trades at prices ranging from $72.31 to $72.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F11 This transaction was executed in multiple trades at prices ranging from $65.045 to $66.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F12 This transaction was executed in multiple trades at prices ranging from $66.045 to $66.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F13 This transaction was executed in multiple trades at prices ranging from $67.095 to $67.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F14 All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F15 Twelve and one-half percent (12.5%) of the shares subject to the Option vest upon the date following the acceptance by the US FDA of an NDA submission for DCCR, twelve and one-half percent (12.5%) of the shares subject to the Option vest upon the submission by the Company to the European Medicines Agency European of an MAA for DCCR, and one forty-eighth (1/48th) of the remaining shares subject to the Option vest each month anniversary of January 8, 2021 (the "Vesting Commencement Date") on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F16 One forty-eighth (1/48th) of the shares subject to the Option vested on the first month anniversary of January 1, 2022 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F17 One forty-eighth of the shares subject to the option vest on February 1, 2023 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.
F18 One thirty-sixth of the shares subject to the Option vest on June 26, 2023 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.